NCT04677595 - Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

October 12, 2023

Study Completion Date

May 22, 2025

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Capmatinib

400 mg of capmatinib tablets, administered orally twice daily

Trial Locations (17)

100036

Novartis Investigative Site, Beijing

110011

Novartis Investigative Site, Shenyang

150081

Novartis Investigative Site, Harbin

200032

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

250117

Novartis Investigative Site, Jinan

300052

Novartis Investigative Site, Tianjin

310022

Novartis Investigative Site, Hangzhou

361001

Novartis Investigative Site, Xiamen

430022

Novartis Investigative Site, Wuhan

450003

Novartis Investigative Site, Zhengzhou

510080

Novartis Investigative Site, Guangzhou

510120

Novartis Investigative Site, Guangzhou

510515

Novartis Investigative Site, Guangzhou

528000

Novartis Investigative Site, Foshan

610041

Novartis Investigative Site, Chengdu

650106

Novartis Investigative Site, Kunming